# Safety and Efficacy Studies of Panobinostat and Bicalutamide in Patients With Recurrent Prostate Cancer After Castration

> **NCT00878436** · PHASE1,PHASE2 · COMPLETED · sponsor: **NYU Langone Health** · enrollment: 52 (actual)

## Conditions studied

- Prostate Cancer
- Prostatic Neoplasms

## Interventions

- **DRUG:** Panobinostat
- **DRUG:** Bicalutamide

## Key facts

- **NCT ID:** NCT00878436
- **Lead sponsor:** NYU Langone Health
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-06
- **Primary completion:** 2015-03
- **Final completion:** 2015-07
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2018-02-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00878436

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00878436, "Safety and Efficacy Studies of Panobinostat and Bicalutamide in Patients With Recurrent Prostate Cancer After Castration". Retrieved via AI Analytics 2026-06-13 from https://api.ai-analytics.org/clinical/NCT00878436. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*